These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 36465444)

  • 1. PAH-specific therapy for pulmonary hypertension and interstitial lung disease: A systemic review and meta-analysis.
    Zhao N; Chen J; Zhang M; Zhou L; Liu L; Yuan J; Pang X; Hu D; Ren X; Jin Z
    Front Cardiovasc Med; 2022; 9():992879. PubMed ID: 36465444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic use of PAH-specific therapy in World Health Organization Group III Pulmonary Hypertension: a systematic review and meta-analysis.
    Prins KW; Duval S; Markowitz J; Pritzker M; Thenappan T
    Pulm Circ; 2017 Mar; 7(1):145-155. PubMed ID: 28680574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
    Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
    Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Six-minute walk test in systemic sclerosis: A systematic review and meta-analysis.
    Vandecasteele E; De Pauw M; De Keyser F; Decuman S; Deschepper E; Piette Y; Brusselle G; Smith V
    Int J Cardiol; 2016 Jun; 212():265-73. PubMed ID: 27057932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
    J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haemodynamic effects of PAH-targeted therapies in pulmonary hypertension due to lung disease: A systematic review and meta-analysis.
    Farmakis IT; Vazakidis P; Doundoulakis I; Arvanitaki A; Zafeiropoulos S; Boutou A; Karvounis H; Giannakoulas G
    Pulm Pharmacol Ther; 2021 Jun; 68():102036. PubMed ID: 33979684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies.
    Le Pavec J; Girgis RE; Lechtzin N; Mathai SC; Launay D; Hummers LK; Zaiman A; Sitbon O; Simonneau G; Humbert M; Hassoun PM
    Arthritis Rheum; 2011 Aug; 63(8):2456-64. PubMed ID: 21538327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary hypertension inhaled therapies: An updated review.
    El-Kersh K; Jalil BA
    Am J Med Sci; 2023 Jul; 366(1):3-15. PubMed ID: 36921672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A PrOsPective Cohort Study on Interstitial Lung Disease-Associated Pulmonary Hypertension with a ParticulaR Focus on the Subset with Pulmonary Arterial Hypertension Features (POPLAR Study).
    Tsujino I; Kitahara K; Omura J; Iwahori T; Konno S
    Pulm Ther; 2024 Sep; 10(3):297-313. PubMed ID: 38913242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study.
    Waxman A; Restrepo-Jaramillo R; Thenappan T; Engel P; Bajwa A; Ravichandran A; Feldman J; Hajari Case A; Argula RG; Tapson V; Smith P; Deng C; Shen E; Nathan SD
    Eur Respir J; 2023 Jun; 61(6):. PubMed ID: 37080567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostacyclin for pulmonary arterial hypertension.
    Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
    Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical phenotypes, hemodynamic characteristics and prognosis of Chinese patients with systemic sclerosis-associated precapillary pulmonary hypertension: a retrospective study.
    Yuan YP; Yuan P; Su YL; Jiang R; Zhang R; He J; Qiu HL; Luo CJ; Liu JM; Gong SG; Wang L; Zhao QH
    Clin Rheumatol; 2022 Jun; 41(6):1675-1686. PubMed ID: 35099674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
    Mathai SC; Hummers LK; Champion HC; Wigley FM; Zaiman A; Hassoun PM; Girgis RE
    Arthritis Rheum; 2009 Feb; 60(2):569-77. PubMed ID: 19180517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective, longitudinal study evaluating the baseline six-minute walk test as an individual reference value in systemic sclerosis patients.
    Vandecasteele E; Melsens K; De Keyser F; De Pauw M; Deschepper E; Decuman S; Piette Y; Thevissen K; Brusselle G; Smith V
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):95-101. PubMed ID: 30183593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient and Therapeutic Profiles of Pulmonary Hypertension in Chronic Lung Diseases in Japan: A Cohort Study Using a Claims Database.
    Kitahara K; Omura J; Wada S; Kim SW
    Pulm Ther; 2024 Mar; 10(1):21-49. PubMed ID: 37950789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
    Michelfelder M; Becker M; Riedlinger A; Siegert E; Drömann D; Yu X; Petersen F; Riemekasten G
    Clin Rheumatol; 2017 Feb; 36(2):381-390. PubMed ID: 28028682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Riociguat therapy for pulmonary hypertension: a systematic review and meta-analysis.
    Wang L; Zhu L; Wu Y; Li Q; Liu H
    Ann Palliat Med; 2021 Oct; 10(10):11117-11128. PubMed ID: 34763472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort.
    Noviani M; Saffari SE; Tan JL; Yip JWL; Teng GG; Law WG; Chan GYL; Santosa A; Lim AYN; Hong C; Ng SA; Tay ELW; Ruan W; Yap J; Low AHL
    Semin Arthritis Rheum; 2020 Jun; 50(3):473-479. PubMed ID: 31810742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension.
    Petrovič M; Locatelli I
    Ann Pharmacother; 2020 May; 54(5):423-433. PubMed ID: 31735058
    [No Abstract]   [Full Text] [Related]  

  • 20. Guanylate cyclase stimulators for pulmonary hypertension.
    Wardle AJ; Seager MJ; Wardle R; Tulloh RM; Gibbs JS
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD011205. PubMed ID: 27482837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.